Speakers Charité Entrepreneurship Summit 2014

Co-Chairs

E. Jürgen Zöllner

E. Jürgen Zöllner has been Executive Director of Stiftung Charité since May 2012. Before that, he served as Senator for Education, Youth and Science in Berlin (2006-11) and as Minister for Education, Science, Further Education and Culture in Rhineland-Palatinate (1991-2006). Previous to his political career E. Jürgen Zöllner was President of Johannes Gutenberg University Mainz. He studied medicine at the University of Freiburg and Johannes Gutenberg University Mainz and was a full professor at the latter institution for many years.

Karl Max Einhäupl

Prof. Dr. Karl Max Einhäupl is Chairman of the Executive Board of the Charité – Universitätsmedizin Berlin and has served in this position since 2008. He is one of the most distinguished neurologists in Germany and from 2001-2006 served as the President of the Scientific Advisory Council to the German Federal Government (Wissenschaftsrat). During his scientific career he has received numerous awards and is a member of the Leopoldina, the National Academy of Sciences in Germany. Since 2013 Prof. Einhäupl has been a Member of the Board of Directors of the Berlin Institute of Health (BIH).

Confirmed Speakers

Dominik Böhler

Dr. Dominik Böhler is manager of the UnternehmerTUM unit “Lectures & Seminars” and thus responsible for the education of students and PhD students, as well as for lecturing. He holds a diploma in business administration, with a major in entrepreneurship, and a PhD in information systems. During his studies he was self-employed as an IT consultant.

Veronique Bouchet

Dr Veronique Bouchet has over 25 years experience in the healthcare industry, and is the founder director of Novudel Associates, a life sciences consulting and coaching company. Prior to this she was director of corporate strategy and head of venture capital relations at AstraZeneca PLC. In addition she has held a variety of senior international roles in the pharmaceutical industry across several therapeutic areas and functions including drug development, medical marketing, business development, M&A, corporate strategy and in venture capital. She is a non-executive director of International Biotechnology Trust plc, an investment trust listed on the LSE, and of the Stevenage Bioscience Catalyst, the UK’s first Open Innovation campus, which is a joint venture between GSK and the Welcome Trust. Veronique is a trustee of Breast Cancer Campaign UK and a member of the Council of Queen Mary, University of London. She is also a member of BACIT LP’s special advisory committee, which assesses investments in projects undertaken by the Institute of Cancer Research. She has an MB BS from St Bartholomews’ Hospital Medical School, holds a BSc in Psychology from University College London, and a Diploma from the Royal...
Michael Brandkamp

Dr. Michael Brandkamp is the Executive Director of High-Tech Gründerfonds and has focused on the investment business for young technological companies since 1997. In 2004 and 2005, he was the Department Manager for Innovation Financing and Shareholdings within the KfW banking group, and was previously the Associate Executive Director of tbg Technologie-Beteiligungs-Gesellschaft mbH of the Deutsche Ausgleichsbank. In 1999 he became the Director of the tbg Berlin office. He studied Economics at the Universities of Münster, Nairobi and Bonn and earned his PhD at the Technische Universität Freiberg (Saxony) at the Chair for Business Management Innovation Research.

Pablo Cironi

Dr. Cironi holds a B.Sc. in Chemistry from the University of Buenos Aires, and a Ph.D. in Organic Chemistry from the University of Barcelona, where he focused on the design and synthesis of complex marine natural products in solid phase. From 2005 to 2009 he was a Fulbright postdoctoral Fellow at the Department of Systems Biology at Harvard University, during which he worked on different aspects of Synthetic Biology, Protein Design and Engineering, in addition to successfully developing a novel technology for designing novel protein therapeutics. In 2008 Dr. Cironi’s work was awarded with the Accelerator Funds from Harvard University. In 2009 he joined the Botín Foundation as Senior Innovation & Technology Transfer Manager, where he was responsible for identifying new business opportunities, managing IP portfolio and defining business strategies to bring academic and public-based research results to market. In 2013 Dr. Cironi joined the Center for Genome Regulation (Barcelona) to Head the Technology Transfer department, where his main role consists of channeling CRG’s discoveries to market. CRG research activities focus mainly in genomics, gene transduction and regulation, systems biology, bioinformatics and personalized medicine. Dr. Cironi has gathered over 14 years of research and development experience in the Drug Discovery, Molecular and Synthetic Biology, and in Biologics, and 6 years managing technology transfer and commercialization processes. Dr. Cironi has acquired a unique and strong acumen in commercialization strategy and innovation.

Barbara Clarke

Barbara Clarke has over a decade of international management consulting experience with KPMG and PricewaterhouseCoopers where she specialized in intellectual property valuations. She left the corporate world to launch several large, national nonprofits. Barbara returned to for-profit ventures as an angel investor, most notably with Astia Angels. On her portfolio she prefers big data analytics to leverage her background as an economist. Barbara received a BA in Quantitative Economics from Tufts University and a Masters in International Economics and Finance from Brandeis University.

Dorothée Marie-Louise Döpfer

Dorothée Marie-Louise Döpfer is consultant at the technology transfer unit (profund) of Free University Berlin. Her area of expertise is networking, partnerships, and fundraising. In addition, she initiated the first mentoring program for young entrepreneurs at a university in Berlin. Dorothée holds a minor in sociology and a major in history from KIT
Jorge Juan Fernández García

Jorge Juan Fernández García is the Director of e-Health and Health 2.0 at Hospital Sant Joan de Déu (Barcelona), one of the largest children’s hospitals in Europe. He is also the Head of Academics at Moebio, where he leads the d’HEALTH Barcelona program. Jorge has over 15 years of experience in life sciences and healthcare, working on projects throughout Europe, with a strong focus on technology, innovation and entrepreneurship. He regularly acts as advisor and mentor to various healthcare start-ups and entrepreneurial acceleration programs. Jorge is a graduate from the London School of Economics (LSE). He also holds a GMP from IESE Business School and a GSP from Singularity University. He has been recently selected as 2014 European Young Leader “40 Under 40”.

Johannes Fruehauf

Dr. Fruehauf is the Founder and President of LabCentral, a non-profit, shared laboratory facility designed to accelerate the formation of new life science companies and to create a central hub for the early-stage biotech activity in Kendall Square, Cambridge. Before that, he was co-founder and Head of R&D of Cequent Pharmaceuticals (sold to Marina Biotech; NASDAQ: MRNA). He is the Founder and President Cambridge Biolabs (CBL), a research service laboratory that has become one of the most successful incubators for life science companies in the Boston area. He is actively involved in mentoring startup companies and non-profits through MassChallenge and BioInnovation and serves as a Board member or co-founder at ViThera Pharmaceuticals, MassLander, T1DFirst, Deltix, BMT and the German International School Boston. Dr. Fruehauf holds a medical degree from the University of Frankfurt and a PhD from University of Heidelberg (Germany). Dr. Fruehauf is a named inventor on 15 patents in molecular biology and drug delivery and author on over 30 peer reviewed articles. He blogs and tweets at @jfruehauf and @labcentral.

Steve Gardner

Dr Steve Gardner has over 20 years of experience and a strong track record of building world-class companies, teams and products within the life science and healthcare industries. He specializes in designing and delivering advanced semantic integration and search systems and has raised over £50M, participated in an LSE flotation and 11 corporate acquisitions. In his role as CTO of BioWisdom he worked on over 25 safety, regulatory and marketing projects for major pharmaceutical companies and provided the informatics support to the InnoMed (Alzheimer’s biomarkers) project for the EU under the FP6 programme. Steve was a lead contributor to the €2B EU IMI programme’s Strategic Research Agenda. Steve was founder and CEO of Synomics Ltd and European MD and CTO for Viaken Systems. Prior to that, Steve was Worldwide Director of Research Informatics for Astra AB, and as Senior Product Manager at Oxford Molecular, he coordinated the senior scientific advisory meetings including four Nobel Laureates.
Rowan Gardner

Rowan Gardner is a life science strategy and business development professional with a substantial network of investor contacts that participate in all stages of company creation and growth. As Head of Investor Relations at Oxford Molecular (an LSE main market listed Oxford University spin out) she worked with the Board and the company’s financial advisors to develop and deliver the corporate communications, IR and PR strategies. Rowan maintains close relationships with various industry groups such as Astia, PRISM, and Atlantic BioBridge. She has consulted to various UK RDAs, SMEs and financial institutions to help broker, fund and develop new initiatives. Rowan has recently led projects to develop world class biobanking and bioprocessing capabilities in various UK regions.

Georg Greitemann

Dr. Georg Greitemann is a partner in the Frankfurt office of P+P Pöllath + Partners. He has been advising on venture capital transactions throughout his legal career, starting 2003 as an associate in the Munich office of P+P. P+P is recognized as one of the German market leaders on the legal and tax structuring of venture capital transactions. Over the years, Georg has worked on several cross border transactions with Michael McGrail. He studied law and economics at the Universities of Freiburg, York, Heidelberg and Cornell.

Katya Hancock

Katya Hancock is a passionate advocate for health entrepreneurs and an active member of the startup technology ecosystem. Katya is the Strategic Partnerships Director at StartUp Health, an Academy to inspire, educate, and provide resources for entrepreneurs to build innovative health and wellness tech companies. At StartUp Health, Katya focuses on building strategic partnerships that unite entrepreneurs with key industry stakeholders focused on health and wellness innovation. Prior to StartUp Health, Katya worked at the investment bank CIBC Oppenheimer before moving to the technology industry helping build three financial tech startups. Katya joined each startup early to craft their go-to-market and commercialization strategies, helping two of them grow to be acquired by Fortune 500 companies, Thomson Reuters and Morningstar. Her experience includes strategic partnerships and business development, enterprise sales, channel sales partnerships, product management, marketing, and capital raising. Katya earned her BS in Economics from California Polytechnic University in San Luis Obispo, CA. Katya lives in New York City.

K. Peter Hirth

Dr. Hirth is a life-science advisor and angel investor and has over 25 years of biotechnology and pharmaceutical discovery and development experience. He was a co-founder and CEO of Plexxikon were he built a novel, structure-guided drug discovery platform, which over the last ten years, has brought several NCEs into the clinic in a variety of indications. Most advanced from this portfolio is a V600E B-raf selective inhibitor that was FDA approved for metastatic melanoma together with a companion diagnostic and is sold under the brand name Zelboraf™. After Plexxikon was acquired in April 2011 by Daiichi Sankyo, Dr. Hirth had agreed to stay for a two year transition period until April 2013. Previously, he was at Sugen, Inc. from 1991 until 2000 and helped build the company from its inception and advanced several kinase inhibitors through clinical trials in oncology. Sutent was the first Sugen product to reach the market in renal cell carcinoma. After the acquisition of Sugen by Pharmacia Upjohn in 1999, Dr. Hirth stayed
on to help with the integration until 2000. At Sugen, Dr. Hirth held several positions with increasing responsibilities, last as President. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company's erythropoietin program to approval in 1989, sold under the name Recormon. Before joining Boehringer Mannheim, Dr. Hirth was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany. Dr. Hirth serves as a director on the Boards of Kolltan Pharmaceuticals in New Haven, CT, Alios Biopharma, in San Francisco, CA and Kinemed in Emeryville, CA.

**Ulrich Kintscher**

Prof. Kintscher received his M.D. from the University of Hamburg, Germany. He is board-certified in Internal Medicine and Pharmacology. In 2006 he was appointed as a Full Professor of Pharmacology at the Charité-Universitätsmedizin Berlin, Germany. He is currently the Acting Director of the Institute of Pharmacology, and Director of the Center for Cardiovascular Research at the Charité-Universitätsmedizin Berlin, Germany. Since 2013, he is chairing the Clinical Trial Management Unit (CTMU) of the Charité, a central service unit for all Charité clinics in the area of industry-sponsored trials. The major scientific interest of Prof. Kintscher is the identification of new pharmacological targets to treat metabolic disease and associated cardiovascular pathologies. He is author of multiple peer-reviewed scientific articles.

**Jochen Klupp**

Dr. Jochen Klupp has as Senior Global Program Head Transplantation final accountability for the innovation, strategy, operations, and related development deliverables for the Novartis transplant portfolio. He also oversees the Medical Affairs Transplant activities and interacts closely with the Global Brand Director of Marketing and Commercial Strategy on branded products, and with Research to guide early development of new compounds. He reports directly to Dr. John Hohneker, Development Franchise Head Integrated Hospital Care and next level to Dr. Timothy Wright, Global Head of Development Novartis.

Dr. Klupp joined Novartis in Translational Medicine in April 2005, being responsible for Proof-of Concept (PoC) studies for immunomodulatory compounds in development for transplantation and autoimmune diseases. In October 2006, he joined the Infectious Disease, Transplantation and Immunology Business Franchise as New Product Medical Director in Clinical Development and Medical Affairs. From 2008 onwards, he led as Global Program Head the development of several phase 2a to phase 3 compounds in the therapeutic areas of transplantation, immunology and dermatology. Until April 2005 Dr. Klupp was heading the liver transplant program at Charité Berlin (Director: Dr. Peter Neuhaus). He was responsible for the coordination of clinical research in the field of Oncological Surgery, Endocrine Surgery and Transplantation. He served as investigator of numerous clinical trials. His preclinical research focused on pharmacokinetic/pharmacodynamic relationships of immunosuppressive compounds, the optimization and personalization of immunosuppressive regimens to increase safety and tolerability of anti-rejection prophylaxis and treatment.

**Ulli Jendrik Koop**

Ulli Jendrik Koop is the founder and CEO of XLHEALTH, an investor for Digital Health start-ups. He envisions the future of digital health to enable medical users to improve their health by using, sharing and creating sustainable knowledge. Prior to the founding of XLHEALTH, he worked in the strategic department of CompuGroup Medical, one of the
leading eHealth companies in the world that develops software products and services to support all medical and organizational activities of healthcare providers. He gathered both strategic and operational expertise throughout Europe and the United States. Ulli studied in Shanghai, Aachen and Vallendar and obtained a Master’s degree from WHU – Otto Beisheim School of Management.

**Christian Krey**

Dr. Christian Krey is Chief Executive Officer of Emperra E-Health Technologies and has distinctive expertise for the German market, especially in the field of diabetes. He has worked for over 16 years in different positions in the medical device industry, always focused on the benefit for patients. He worked for Lilly Deutschland and Berlin-Chemie for several years in Sales and Marketing departments. In 2008 he switched to A. Menarini diagnostics (Division of Berlin-Chemie) to build up a marketing department for their blood glucose meter business. In 2011 he became Business Unit Manager for Animas, a Johnson & Johnson Company, to build up the German business unit for insulin pumps and continuous glucose sensors. He studied chemistry at the University of Kiel and earned his PhD 1997 with experimental work in physical chemistry.

**Peter Mayer**

Dr. Peter Mayer is Partner in Dentons’ Berlin office and specializes in corporate law as well as mergers and acquisitions with an industry focus on energy and chemistry. He is Head of Dentons’ Energy practice in Germany. He has a vast experience in representing coal power plant operators as well as wind farm and solar plant operators and project developers in the renewable energy sector in the areas of corporate and energy law. He represents various foreign investors, mainly from the US, the Middle East and China regarding their investments and corporate joint ventures in Germany and other parts of Europe.

**Michael J. McGrail**

Michael J. McGrail is a partner in the Cooley Business department and a member of the Firm's Mergers & Acquisitions, Medical Devices, Venture Capital Financings and International practice groups. He joined the Firm in 2007 and is resident in the Boston office. Mr. McGrail's practice includes the representation of company and investor clients in a full range of corporate legal projects, including mergers and acquisitions, private financings, corporate partnerships and technology licensing. He counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. Mr. McGrail is fluent in German, and a significant portion of his practice is devoted to international transactions. Prior to attending law school, Mr. McGrail served as the Head of Regulatory Affairs at a German manufacturer of medical devices. Before joining Cooley, Mr. McGrail was an associate in the Medical Device Practice at Hogan & Hartson in Washington, DC, with a focus on commercial, licensing and FDA regulatory issues. Mr. McGrail earned his JD from Boston College Law School, graduating *cum laude*, in 2001. He earned his BA from Northeastern University, graduating *magna cum laude*, in 1993. Mr. McGrail has been selected as a *Massachusetts Super Lawyers “Rising Star”* each year since 2009.
Christoph Meinel

Dr. Meinel is Head and Executive Director of the Hasso-Plattner-Institute (HPI) and a full professor at the University of Potsdam. He is a member of the National Academy of Science and Engineering (acatech) and an honorary professor at the Technical University of Beijing. Internet technologies and systems are in the center of the research and teaching of the chair of Christoph Meinel. He and his team are focused on Big Data, cloud computing, in-memory technology, and future Internet applications in areas like security, Web 3.0, and e-learning. In addition, he conducts research in the field of innovation, especially on the Design Thinking method. Together with Larry Leifer he serves as Program Director of the HPI – Stanford Design Thinking research program.

Lesa Mitchell

Former Vice President at Ewing Marion Kauffman Foundation, Mitchell designed and implemented programs to accelerate economic growth in a variety of sectors (life science, technology, hardware, energy). Mitchell is now an active coach (TED Fellows, SXSW), board member at Modern Meadow, Humin, HarpHealth, CapLinked, Enstitute and the Althea Foundation. Mitchell also works for CEO’s of early stage companies focused on scale in new markets. Mitchell spent twenty years as an executive in the pharmaceutical industry supporting design, development and implementation of new technologies and process as well as providing leadership in post M&A roles.

Abhi Naha

Abhi Naha is the CEO and Founder of Zone V Ltd a Cambridge UK start up backed by Qualcomm and ARM Holdings. Zone V is focused on empowering blind people through inclusively designed mobile devices with a strong focus on empowering women in developing countries. Of the 284 million blind and partially sighted people in the world two thirds of all blind people are women and ninety per cent live in developing countries. Abhi Naha is also a Board Advisor to EqualEyes, part of Wayra (Telefonica) and founder of the Cambridge Wireless handset special interest group which he now co-chairs with Qualcomm and Accenture. Previously he held senior management roles at Powermat and Idem. Idem is a Finnish handset design firm with over 100 million handsets in the market from four of the top Tier 1 Handset Oems in the world. Prior to that he was a senior manager at a Silicon Valley mobile touchscreen and user interface technology provider, Synaptics. Abhi Naha is an Ex Chairman of the UK based charity ‘Beatbullying’, mentor for the Princes Trust and Vice President of the Communications and Manufacturing Association of India. He has also held advisory roles for Goldman Sachs and Silver Lake in the area of mobile handset user interface technologies. Abhi Naha along with his friend Peter Whale of Qualcomm recently had their first book published by Cambridge University Press entitled ‘Mobile Handset Design’. Abhi Naha holds a MBA from Aston Business School and BSc (Honours) degree in Electronics Engineering from Leicester University.

Nikolaus Rajewsky

Nikolaus Rajewsky is a full professor at the Max Delbrück Center for Molecular Medicine (MDC) and Scientific Director of the Berlin Institute for Medical Systems Biology (BISMB) in Berlin. With a background in mathematics and physics, Nicholas Rajewsky, following his doctorate in theoretical physics in Cologne and postdoctoral periods in New Jersey and at Rockefeller University, New York, turned to systems biology. After an assistant professorship at New York University, he returned to Germany in 2006. In 2012, he was awarded the Gottfried Wilhelm Leibniz Prize, endowed with € 2.5 million, by the German Research Foundation (DFG). His work combines physics and mathematics with systems
biology, which examines the regulatory processes in whole cells or organisms across the genome or proteome. Of particular importance is Rajewsky’s work on microRNAs, small non-coding RNAs that play a key role in controlling cellular processes, but also in the development of cancer and other diseases. A computer program developed under Rajewsky’s guidance made it possible for the first time to identify the target genes of microRNAs. Using another technology, the strength of the effect of microRNA regulation on protein synthesis could be described.

Jørgen Schlundt

Jørgen Schlundt, Director, National Food Institute at Technical University of Denmark, has a Veterinary Degree (DVM) as well as a Ph.D. from the Royal Veterinary and Agricultural University in Copenhagen, Denmark. He worked at national level on environmental and food safety issues from 1983 to 1999, during which period he headed the Bacteriology Department at the Veterinary Research Laboratory in Harare, Zimbabwe for three years. From 1999 – 2010 Dr. Schlundt was Director of the Department of Food Safety and Zoonoses at WHO, Geneva. He has participated in a number of international bodies, including OECD expert groups, WHO and FAO Expert Consultations, EU Scientific Committees, and the FAO/WHO Codex alimentarius Commission. JS has participated in the international development of Risk analysis principles, including the use of scientific risk assessment as the basis for food safety management decisions. As part of this, he has overseen major new international initiatives, including the creation of the Joint WHO/FAO Joint Expert meeting on Microbiological Risk Assessment (JEMRA) and the International Food Safety Authorities Network (INFOSAN), the build-up of the Global Foodborne Infections Network (GFN), the initiation of the first-ever estimation of the global burden of foodborne diseases, and the development of a major consumer education programme on the Five Keys to Safer Food.

Johannes Schneider-Littfeld

Johannes Schneider-Littfeld earned a BSc,MSc in Biomedical Engineering and has been working in biomedical research in endocrinology for several years. He then started his industry career at the international consulting firm Sudler&Hennessy Healthcare followed by leading positions as managing director/CEO at Disetronic, Becton-Dickinson and Bauerfeind. He successfully started businesses in new territories like Eastern Europe and Asia as well as brought new technologies from development to market. At Ottobock he is Corporate Vice President and leading the Business Unit Neurostimulation. He is Board Member of various international Healthcare companies.

Ulrich Schriek

Dr. Ulrich Schriek, Senior Vice President of Corporate Business Development has played a critical role in shaping QIAGEN’s growth strategy and is an integral player in driving its successful execution. He joined QIAGEN in 1997 and was appointed to Vice President of Corporate Business Development in 2000. Dr. Schriek’s track record includes more than 45 successful acquisitions with a total value over USD 2 billion and more than 250 licensing transactions, helping to continuously grow QIAGEN’s business scope and international presence. Dr. Schriek has over 30 years of experience in the biotechnology industry. Prior to joining QIAGEN, he held sales and marketing positions at Pharmacia Biotech. Dr. Schriek holds a Master’s degree in science and obtained his Ph.D. in biochemistry from the Ruhr-University Bochum in Germany. He is member of various industry panels and organizations, including the World Economic Forum Technology Pioneers Selection Committee and the High-Tech Gründerfonds (HTGF) in Germany.
Dr. Alexander Schuth leads the global partnering activities for Genentech in the neuroscience field. His team is responsible for sourcing and executing collaboration opportunities with industry and academic partners to enable the discovery and development of new breakthrough medicines. Transactions span across the full spectrum of deal structures, including product in-licenses, research collaborations, co-development agreements, spin-offs and M&A. In addition, Alex is the point of contact in Genentech's partnering group for companies, academic institutions and investors in Germany, Switzerland and Austria, across all therapeutic areas. Alex is a physician by training and completed his medical degree at the Charité in Berlin and also holds an MBA from the Wharton Business School. Before joining Genentech in 2005, Alex worked in the investment banking group at Merrill Lynch in London, where he was involved in several capital market transactions in the health care sector.

Klaus Stoeckemann

Klaus Stoeckemann is Managing Partner & Co-Founder of Peppermint VenturePartners (PVP) a private venture capital firm based in Berlin, Germany. PVP manages and currently invests out of the Peppermint Charité Biomedical Fund 1 which is focusing on medical device, diagnostic and m-health start-up opportunities mainly in Europe. Before starting PVP, Klaus was a General Partner in 3i’s international Healthcare Venture Team. He has more than 12 years Pharma experience with leading roles in R&D and Business Development. He holds a Ph.D in Biology and Pharmacology from the University Mainz, Germany as well as a MBA from WHU / Kellogg Northwestern University in the US. Klaus has more than 14 years Venture Capital Industry experience and was responsible for investments and IPO’s such as for example Epigenomics, Jerini as well as the trade sales of Evotec Neuroscience, Amaza and Elbion. Klaus has been board member of several Biotech and medical device companies such as Epigenomics, Jerini, Elbion, Evotec Neuroscience, Amaza, Immatics as well as IntellIDx and Zonare in the US. He focuses on medical devices and Health IT / mobile health investments and is currently chairman of the boards of Humedics and Emperra and board member of Implandata Ophthalmic Products.

Sharon Terry

Sharon F. Terry is President and CEO of Genetic Alliance, a network of more than 10,000 organizations, of which 1,200 are disease advocacy organizations. Genetic Alliance enables individuals, families and communities to reclaim their health and become full participants in translational research and services. She is the founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). As co-discoverer of the gene associated with PXE, she holds the patent for ABCC6 to act as its steward and has assigned her rights to the foundation. She developed a diagnostic test and conducts clinical trials. Terry is also a co-founder of the Genetic Alliance Registry and Biobank. She is the author of more than 90 peer-reviewed articles. In her focus at the forefront of consumer participation in genetics research, services and policy, she serves in a leadership role on many of the major international and national organizations, including the Institute of Medicine Science and Policy Board, the IOM Roundtable on Translating Genomic-Based Research for Health, the National Coalition for Health Professional Education in Genetics Board, the International Rare Disease Research Consortium Interim Executive Committee and as a member of the Board of Instigators for InvokeHealth! She is on the editorial boards of several Journals. She was instrumental in the passage of the Genetic Information
Nondiscrimination Act. In 2005, she received an honorary doctorate from Iona College for her work in community engagement; the first Patient Service Award from the UNC Institute for Pharmacogenomics and Individualized Therapy in 2007; the Research!America Distinguished Organization Advocacy Award in 2009; and the Clinical Research Forum and Foundation's Annual Award for Leadership in Public Advocacy in 2011. In 2012, she became an honorary professor of Hebei University in China, and also received the Facing Our Risk of Cancer Empowered (FORCE) Spirit of Empowerment Award. She is an Ashoka Fellow.

Ida Tin

Ida Tin is the founder and CEO of Clue, a digital female health company based in Berlin, Germany whose app is acclaimed as the most streamlined, user-friendly menstrual cycle tracking app available. Ida graduated from Denmark's prestigious creative business school, KaosPilots. A lifelong entrepreneur, she previously led motorcycle tours around the world and published a book about her experience, “Direktøs” which became a Danish bestseller.

Ulrich Vollmer

Ulrich Vollmer studied mathematics at the Friedrich-Schiller-Universität Jena and obtained his doctorate in computer science at the Technische Universität Darmstadt in 2003. He held scientific and teaching positions at MIT, the Escuela Politécnica Nacional Quito, the Ludwig-Maximilians-Universität München and Technische Universität Darmstadt. Since 2008 he works for the Berlin Commissioner for Data Protection and Freedom of Information. There he is responsible for regulatory activities in the field of medical IT, and advises on the application of cryptographic techniques and privacy enhancing technologies. On the federal level, he coordinated the publication of an official guide for the design and use of medical information systems from the data protection point of view. The content of the talk is joint work with Ms. Anke Virks, attorney at law with the Berlin Commissioner for Data Protection and Freedom of Information.

Sharon Vosmek

Sharon Vosmek has been CEO of Astia since 2007, previously joining as COO in 2004. As CEO of Astia, Sharon has an unwavering passion and a uniquely well-suited background to drive forward the organization’s mission of propelling women’s full participation as entrepreneurs and leaders in high-growth businesses, fueling innovation and driving economic. Under her guidance, the Astia community of investors, entrepreneurs, and industry leaders has grown from 20 individuals in Silicon Valley; to more than 5,000 around the globe, representing every continent. Previously, Sharon founded SJ Vosmek & Associates and held management positions at American Express and in the office of U.S. Senator Dennis DeConcini. Ms. Vosmek currently serves as founder and lead of the We Own It Collaboration, an effort of over 65 organizations globally committed to exploring women’s participation in high growth businesses and identifying solutions to move us forward. She also currently serves on the Advisory Boards of two venture capital firms: StarVest Partners and Illuminate Ventures; the Stevenage Bioscience Catalyst Experts Advisor Group; the AAAS-Lemelson Invention Ambassadors Advisory Committee; and on the "Making Value for America" expert advisory committee for the National Academy of Engineering. Sharon has a master’s in public policy and administration from the University of Wisconsin, Madison and a bachelor's in political science from Arizona State University.